CRVO (CervoMed) Days Payable : 0.00 (As of Sep. 2024)

View and export this data going back to 1996. Start your Free Trial

What is CervoMed Days Payable?

CervoMed's average Accounts Payable for the three months ended in Sep. 2024 was $0.90 Mil. CervoMed's Cost of Goods Sold for the three months ended in Sep. 2024 was $0.00 Mil.

The historical rank and industry rank for CervoMed's Days Payable or its related term are showing as below:

CRVO's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 127.37
* Ranked among companies with meaningful Days Payable only.

CervoMed's Days Payable stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00). stayed the same

CervoMed Days Payable Historical Data

The historical data trend for CervoMed's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CervoMed Days Payable Chart

CervoMed Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

CervoMed Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of CervoMed's Days Payable

For the Biotechnology subindustry, CervoMed's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CervoMed's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CervoMed's Days Payable distribution charts can be found below:

* The bar in red indicates where CervoMed's Days Payable falls into.

CervoMed Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

CervoMed's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0.097	+	0.662)	/	2 )	/	0	*	365
=	0.3795					/	0	*	365
=	N/A

CervoMed's Days Payable for the quarter that ended in Sep. 2024 is calculated as:

	Days Payable (Q: Sep. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2024 )	+	Accounts Payable (Q: Sep. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
=	( (0.726	+	1.082)	/	2 )	/	0	*	365 / 4
=	0.904					/	0	*	365 / 4
=	N/A

CervoMed Days Payable Related Terms

Thank you for viewing the detailed overview of CervoMed's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

CervoMed Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CervoMed Inc (NAS:CRVO) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 Park Plaza, Suite 424, Boston, MA, USA, 02116

Website

https://www.cervomed.com

CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Executives

William Robert Elder	officer: GC & Secretary	1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Sylvie Gregoire	director, 10 percent owner	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
John William Tanner	officer: Chief Financial Officer	C/O EIP PHARMA, INC., 20 PARK PLAZA, SUITE 424, BOSTON MA 02116
Frank Zavrl	director	C/O PUMA BIOTECHNOLOGY INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Marwan Sabbagh	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Kelly Blackburn	officer: VP, Clinical Development	C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Jeffrey V. Poulton	director	300 THIRD STREET, CAMBRIDGE MA 02142
John J Alam	director, 10 percent owner, officer: CEO and President	130 WAVERLY STREET, CAMBRIDGE MA 02139
Jill Davidson	director	300 EAST MAIN STREET, SUITE 101, CHARLOTTESVILLE VA 22902
Raven Jaeger	officer: Chief Regulatory Officer	300 EAST MAIN STREET, SUITE 201, CHARLOTTESVILLE VA 22902
Eric Francois	director	C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713
Diana M Lanchoney	director	1317 CARLTON AVE, SUITE 200, CHARLOTTESVILLE VA 22902
Cobuzzi Robert Joseph Jr.	director	C/O DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Christopher D Galloway	officer: Chief Medical Officer	1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Jane H Hollingsworth	director	DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902